US 11,718,670 B2
Methods for determining and achieving therapeutically effective doses of anti-CD47 agents in treatment of cancer
Irving L. Weissman, Stanford, CA (US); Mark P. Chao, Mountain View, CA (US); Ravindra Majeti, Palo Alto, CA (US); Jie Liu, Palo Alto, CA (US); and Jens-Peter Volkmer, Menlo Park, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Sep. 8, 2022, as Appl. No. 17/930,621.
Application 17/930,621 is a continuation of application No. 16/089,115, granted, now 11,472,878, previously published as PCT/US2017/027662, filed on Apr. 14, 2017.
Claims priority of provisional application 62/427,679, filed on Nov. 29, 2016.
Claims priority of provisional application 62/323,330, filed on Apr. 15, 2016.
Prior Publication US 2023/0068235 A1, Mar. 2, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/00 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/24 (2013.01); G01N 2333/70503 (2013.01)] 14 Claims
 
1. A method of treating a human subject for multiple myeloma with a therapeutic dose of anti-CD47 antibody hu5F9-G4, the method comprising:
(a) administering a priming dose of the hu5F9-G4 to the subject, where the priming dose is from about 0.5 to about 5 mg/kg, wherein the priming dose is administered to the human subject in an infusate with a concentration of from 0.05 mg/ml to 0.5 mg/ml hu5F9-G4 delivered over a period of at least 3 hours to reduce severity of hemagglutination; and
(b) administering a therapeutically effective dose of hu5F9-G4 to the subject wherein the therapeutically effective dose is 10-40 mg/kg,
wherein step (b) is after at least about 3 days after beginning step (a), wherein the priming dose primes the subject for administration of the therapeutically effective dose of anti-CD47 antibody such that the therapeutically effective dose does not result in a severe loss of red blood cells.